Pluristem Therapeutics Inc.
PSTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -35.5% | 14.8% | 130.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 36.4% | 35.3% | 31.9% | 60% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,826.9% | -2,145.3% | -1,309.6% | -2,811.9% |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -1,940.5% | 1,834.1% | -1,483.6% | 998.4% |
| EPS Diluted | -0.65 | -1.78 | -0.94 | -0.53 |
| % Growth | 63.5% | -89.4% | -77.4% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | $0 |